Viral Skin Infections Therapeutics
1. Abreva patent expiration
Treatment: Treats cold sores/fever blisters on the face or lips. shortens healing time and duration of symptoms: tingling, pain, burning and/or itching
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5534554 | HALEON US HOLDINGS | Sucrose ester-C20 to C28 alcohol formulations |
Dec, 2013
(12 years ago) | |
| US4874794 | HALEON US HOLDINGS | Inflammatory disease treatment |
Apr, 2014
(11 years ago) | |
Drugs and Companies using DOCOSANOL ingredient
Market Authorisation Date: 25 July, 2000
Dosage: CREAM
More Information on Dosage
ABREVA family patents
2. Veregen patent expiration
Treatment: Treatment of genital warts
VEREGEN IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10434059 | ANI PHARMS | Medicament for the treatment of viral skin and tumour diseases |
Nov, 2022
(3 years ago) | |
| US5795911 | ANI PHARMS | Composition for treating Condyloma acuminata |
Oct, 2020
(5 years ago) | |
| US5968973 | ANI PHARMS | Method for treating hyperplasia |
Apr, 2017
(8 years ago) | |
| US9770406 | ANI PHARMS | Medicament for the treatment of viral skin and tumour diseases |
Jul, 2025
(5 months ago) | |
| US7858662 | ANI PHARMS | Medicament for the treatment of viral skin and tumour diseases |
Oct, 2026
(8 months from now) | |
Drugs and Companies using SINECATECHINS ingredient
Market Authorisation Date: 31 October, 2006
Dosage: OINTMENT
More Information on Dosage
VEREGEN family patents
3. Zelsuvmi patent
expiration
Treatment: Method of administering a nitric oxide releasing active pharmaceutical ingredient to treat and/or prevent viral infection; Method of treating and/or preventing viral infection using a nitric oxide rel...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8956658 | LNHC | Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications |
May, 2026
(4 months from now) | |
| US8282967 | LNHC | Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications |
May, 2026
(4 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11723858 | LNHC | Topical antiviral compositions, delivery systems, and methods of using the same |
Jul, 2035
(9 years from now) | |
| US11040006 | LNHC | Topical antiviral compositions, delivery systems, and methods of using the same |
Jul, 2035
(9 years from now) | |
| US10736839 | LNHC | Topical antiviral compositions, delivery systems, and methods of using the same |
Jul, 2035
(9 years from now) | |
| US10322081 | LNHC | Topical antiviral compositions and methods of using the same |
Jul, 2035
(9 years from now) | |
| US10258564 | LNHC | Topical compositions and methods of using the same |
Nov, 2034
(8 years from now) | |
| US9855211 | LNHC | Topical compositions and methods of using the same |
Feb, 2034
(8 years from now) | |
| US9737561 | LNHC | Topical gels and methods of using the same |
Aug, 2030
(4 years from now) | |
| US9289442 | LNHC | Topical compositions |
Jul, 2032
(6 years from now) | |
| US11285098 | LNHC | Topical compositions and methods of using the same |
Feb, 2034
(8 years from now) | |
| US10376538 | LNHC | Topical gels and methods of using the same |
Aug, 2030
(4 years from now) | |
| US9526738 | LNHC | Topical gels and methods of using the same |
Sep, 2031
(5 years from now) | |
| US10265334 | LNHC | Anhydrous compositions |
Jul, 2032
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 05, 2029 |
Drugs and Companies using BERDAZIMER SODIUM ingredient
NCE-1 date: 06 January, 2028
Market Authorisation Date: 05 January, 2024
Dosage: GEL
More Information on Dosage
ZELSUVMI family patents